...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Biochemical markers in early diagnosis and management of systemic amyloidoses
【24h】

Biochemical markers in early diagnosis and management of systemic amyloidoses

机译:生化标志物在系统性淀粉样糖的早期诊断和管理中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Systemic amyloid diseases are characterized by widespread protein deposition as amyloid fibrils. Precise diagnostic framing is the prerequisite for a correct management of patients. This complex process is achieved through a series of steps, which include detection of the tissue amyloid deposits, identification of the amyloid type, demonstration of the amyloidogenic precursor, and evaluation of organ dysfunction/damage. Laboratory medicine plays a central role in the diagnosis and management of systemic amyloidoses, through the quantification of the amyloidogenic precursor and evaluation of end-organ damage using biomarkers.
机译:全身性淀粉样疾病的特征是广泛的蛋白质沉积,如淀粉样原纤维。准确的诊断框架是正确管理患者的前提。这个复杂的过程是通过一系列步骤实现的,这些步骤包括检测组织淀粉样蛋白沉积物,鉴定淀粉样蛋白类型,证明产生淀粉样蛋白的前体以及评估器官功能障碍/损伤。通过量化淀粉样蛋白生成前体和使用生物标记物评估终末器官损害,实验室医学在全身性淀粉样蛋白的诊断和管理中起着核心作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号